Addition of trastuzumab to chemotherapy has been shown to improve the survival in patients with HER2-positive gastric and GEJ carcinoma in Trastuzumab for Gastric Cancer (ToGA) trial (Bang et al., 2010). This evidence concerns the gene ERBB2 and gastric cancer.